Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial-Reference-Cited by-同舟云学术

Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial

Published:2024-07 Issue:7 Volume:63 Page:1025-1036
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Alexandre Jérôme,Oudard Stephane,Golmard Lisa,Campedel Luca,Mseddi Mourad,Ladoire Sylvain,Khalil Ahmed,Maillet Denis,Tournigand Christophe,Pasquiers Blaise,Goirand Françoise,Berthier Joseph,Guitton Jérôme,Dariane Charles,Joly Florence,Xylinas Evanguelos,Golmard Jean Louis,Abdoul Hendy,Puszkiel Alicja,Decleves Xavier,Carton Edith,Thomas Audrey,Vidal Michel,Huillard Olivier,Blanchet Benoit^ORCID

Funder

Cilag

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40262-024-01396-x.pdf

Reference30 articles.

1. Benoist GE, Hendriks RJ, Mulders PFA, Gerritsen WR, Somford DM, Schalken JA, et al. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016;55:1369–80.

2. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

4. Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. 2023;41:4267–78.

5. Danielak D, Krejčí T, Beránek J. Increasing the efficacy of abiraterone—from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. Eur J Pharm Sci. 2022;176: 106254.